COMP <GO>
AVAH vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Aveanna Healthcare Holdings Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: AVAH 4
— ABBV 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $13.26 (+1.53%) • MKT CAP: $2.89B
roic
15.70%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVAH VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AVAH | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 33.30% | 70.20% | -36.90 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 15.70% | 29.00% | -13.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.5x | 33.3x | -17.80 | AVAH | /valuation <GO> |
| Free Cash Flow Yield | 4.35% | 3.47% | +0.88 | AVAH | /fcf-yield <GO> |
| Operating Margin | 10.50% | 24.60% | -14.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 6.90% | -6.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | 8.60% | +11.60 | AVAH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.86 | 5.33 | -3.47 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | AVAH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.0 | 65.1 | -9.06 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.89B | $513.86B | -$510.97B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AVAH REV | ABBV REV | AVAH GROSS % | ABBV GROSS % | AVAH FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.43B | $61.16B | 33.3% | 70.2% | $125.9M | $17.82B |
| FY 2024 | $2.02B | $56.33B | 31.4% | 70.0% | $32.6M | $17.83B |
| FY 2023 | $1.90B | $54.32B | — | — | $22.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVAH // BETA —
ABBV // BETA 1.15